Conestoga Capital Advisors LLC increased its holdings in shares of Cantel Medical Corp. (NYSE:CMD) by 1.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 737,054 shares of the company’s stock after purchasing an additional 10,008 shares during the period. Cantel Medical Corp. accounts for approximately 3.1% of Conestoga Capital Advisors LLC’s holdings, making the stock its 3rd largest position. Conestoga Capital Advisors LLC owned about 1.77% of Cantel Medical Corp. worth $69,408,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Cantel Medical Corp. during the second quarter worth approximately $376,271,000. Vanguard Group Inc. bought a new stake in shares of Cantel Medical Corp. during the second quarter worth approximately $246,860,000. Neuberger Berman Group LLC bought a new stake in shares of Cantel Medical Corp. during the second quarter worth approximately $96,236,000. Dimensional Fund Advisors LP bought a new stake in shares of Cantel Medical Corp. during the second quarter worth approximately $75,756,000. Finally, Wells Fargo & Company MN bought a new stake in shares of Cantel Medical Corp. during the second quarter worth approximately $75,715,000. Institutional investors and hedge funds own 83.82% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Conestoga Capital Advisors LLC Acquires 10,008 Shares of Cantel Medical Corp. (CMD)” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/01/conestoga-capital-advisors-llc-acquires-10008-shares-of-cantel-medical-corp-cmd.html.
A number of research firms have recently weighed in on CMD. Sidoti upgraded shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cantel Medical Corp. in a research report on Friday, September 1st. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $91.67.
In related news, Director George L. Fotiades sold 6,000 shares of Cantel Medical Corp. stock in a transaction on Friday, October 13th. The shares were sold at an average price of $95.23, for a total value of $571,380.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mark N. Diker sold 7,000 shares of Cantel Medical Corp. stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $98.90, for a total transaction of $692,300.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 36,368 shares of company stock valued at $3,576,028. Insiders own 14.90% of the company’s stock.
Shares of Cantel Medical Corp. (NYSE CMD) traded down 0.41% on Wednesday, reaching $97.68. 30,420 shares of the company’s stock traded hands. The company’s 50-day moving average price is $92.78 and its 200 day moving average price is $80.29. The firm has a market cap of $4.06 billion, a P/E ratio of 57.12 and a beta of 1.25. Cantel Medical Corp. has a one year low of $68.19 and a one year high of $99.83.
Cantel Medical Corp. (NYSE:CMD) last announced its quarterly earnings results on Thursday, September 28th. The company reported $0.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.02. Cantel Medical Corp. had a net margin of 9.27% and a return on equity of 17.60%. The firm had revenue of $205.50 million during the quarter, compared to the consensus estimate of $200.32 million. Cantel Medical Corp.’s revenue was up 14.8% on a year-over-year basis. On average, equities analysts forecast that Cantel Medical Corp. will post $2.34 EPS for the current fiscal year.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
What are top analysts saying about Cantel Medical Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cantel Medical Corp. and related companies.